Sale!

    Enovid Nasal Spary 25ML by SaNOtize 1 bottle

    $149.99 $64.99

    ENOVID – ENOVID NASAL SPRAY
    is a nasal spray with antiviral properties that destroys viruses and creates a physical barrier that prevents viruses from entering the body. Enovid has been scientifically tested and proven to kill 99.9% of viruses in the respiratory tract within 2 minutes. We are clinically tested and found to be safe for use in humans. Nasal spray against viruses approved by the Ministry of Health.

    Shipping is very expensive as we are only shipping it express therefor we are setting a minimum order  of 24 bottles  and price include shipping. no discount coupons are allowed for this product all 24 bottles including shipping will be $1640 meaning bottle price will cost you $68.33 delivered. Each country has its own regulation and customs and it is not our responsibility and the Lab does not accept returns unless damaged.

    Compare

    Description

    ENOVID – ENOVID NASAL SPRAY
    is a nasal spray with antiviral properties that destroys viruses and creates a physical barrier that prevents viruses from entering the body. Enovid has been scientifically tested and proven to kill 99.9% of viruses in the respiratory tract within 2 minutes. We are clinically tested and found to be safe for use in humans. Nasal spray against viruses approved by the Ministry of Health.

    Check the links for more info and studies

    News Listings

     

    slides on UK studyEnovid – MOA

    SaNOtize Research and Development Corp.
    Suite #1-8755 Ash street
    Vancouver, BC V6P 3T3
    EnovidTM, a therapy delivered intranasally, developed by SaNOtize, a
    Vancouver based company with strong ties to Israel, was recently shown to be
    highly effective in reducing viral load of SARS-CoV-2 in positive tested
    patients. Given that the nasal passage is often the primary entry point for SARSCoV-2, interventions administered intranasally could be highly effective in
    limiting spread of COVID-19 infection. enovidTM could be such an intervention.
    Independent testing laboratories have confirmed that enovidTM inactivated
    SARS-CoV-2 virus in-vitro in under 2 minutes (including it’s variants – alpha
    and Gamma. Delta variant in testing) and significantly reduced SARS-CoV-2 in
    infected hamsters. External laboratory testing validated that this treatment also
    inactivated Influenza viruses and other respiratory viruses such as RSV and
    Rhinovirus.
    SaNOtize together with Ashford and St Peter’s Hospitals NHS Foundation
    Trust in Surrey, UK, recently completed a randomised, double blinded, placebo
    controlled trial and showed that enovidTM represents a safe and effective
    virucidal treatment. This treatment can prevent the infection and transmission
    of COVID-19, shorten its course, and prevent the progression of the disease. Specifically, in this clinical
    trial, that evaluated about 80 confirmed cases of COVID-19, SaNOtize’s early treatment for COVID-19
    significantly reduced the level of SARS-CoV-2, as compared to placebo. The average viral log reduction
    in the first 24 hours of treatment was 1.362, which corresponds to a decline of about 95%. Within 72
    hours, the viral load dropped by more than 99%. The majority of these patients had been infected with the
    UK variant, which is considered a variant of concern. The study concluded that enovidTM accelerated
    clearance of SARS-CoV-2 by a factor of 16-fold versus the placebo saline nasal spray (as compared to
    4-5 fold shown in monoclonal antibody testing), and it presents supporting evidence for the use of enovidTM
    for prevention or treatment of patients with recent or established SARS-CoV-2 RNA infection. Since this is
    a non specific virucidal treatment, it can be effective against a wide range of variants and different viruses.
    Given that enovidTM can easily be self-administered as a nasal spray and act as “hand sanitizer for your
    nose”, consideration should be given to its role as an affordable, highly scalable, public health measure for
    prevention of COVID-19 and other similar airborne viral contagions such as influenza.
    Mechanism of Action for the prevention and Treatment of COVID-19
    enovidTM formulation is highly effective at reducing viral load because it has multiple mechanisms of action
    that make it the ideal prevention and treatment for early COVID-19 or other respiratory infections like the
    flu and common cold.
    enovidTM formulation creates a physical and chemical barrier in the nose. The gelling agent creates a
    mechanical barrier which traps viruses within the nasal cavity and prevents them from further entry into the
    respiratory tract causing infection. The first chemical barrier is established by the acid, which lowers the pH
    in the nasal cavity and creates a hostile environment for the virions. The second chemical barrier is created
    by the short (about 5 min) burst of nitric oxide (NO) which enhances the hostile environment. During this
    time, NO rapidly destroys the shape of spikes/protrusions of any virions present, through a process called
    nitrosylation, rendering the key-like viral portion required to enter the cell useless. The other unique
    mechanism of action of enovidTM is that the NO molecule blocks the ACE-2 receptor, preventing the virion
    from fusing to the host cell. This is important because even though NO is produced for a short period of
    time, its effects have a long-lasting protection against viral entry preventing infection of the host cell.
    Confidential and Proprietary
    SaNOtize Research and Development Corp.
    Suite #1-8755 Ash street
    Vancouver, BC V6P 3T3
    Akaberi1
    , a well-respected researcher, was quoted recently saying “To our knowledge, nitric oxide is the
    only substance shown so far to have a direct effect on SARS-CoV-2”
    Nitric oxide is a natural molecule produced by our body and it is widely regarded to possess antimicrobial
    properties. It has been approved, for two decades, as an inhalation treatment for newborn babies with
    pulmonary hypertension, using pressurized gas cylinders. The nitric oxide dose from enovidTM is different
    from the newborn therapy in at least two notable ways. First, enovidTM is being administered topically with
    a liquid made out of compounds approved by the FDA for use in food products, and secondly, enovidTM daily
    NO dose is 0.5% of that approved for the newborns.
    The rationale to evaluate enovidTM in nasal spray for treating COVID-19 is based on its non-systemic, topical
    NO releasing capability showing strong virucidal activity. Delivery of NO releasing liquid to the nasal cavity
    is supported in a recent study that concluded “given that nasal carriage is likely to be a key feature of
    transmission, drugs/vaccines administered intranasally could be highly effective in limiting spread of
    COVID-19 infection”.2
    enovidTM could be used daily, for prevention of infection, supported by the strong human data of
    reducing viral load in the nose. enovidTM could also potentially be used to prevent the progression of
    the disease, in the first few days of symptoms. Daily use of enovidTM will very likely prevent infections.
    Safety
    Nitric oxide gas inhaled continuously in a concentration of 20 parts per million (ppm) for 14 days has been
    approved as a drug to treat newborn babies with pulmonary hypertension, safely, for almost two decades.
    Nitric Oxide is also a natural molecule, produced in every system in our body. enovidTM, delivered as nasal
    spray, has a localized effect and produces nitric oxide at 0.5% of what is approved for treating “blue babies”.
    Further, the compounds used to create the nasal spray are food grade materials in a daily concentration
    under the Average Daily Intake guidelines. There were no adverse health events recorded in over 2000
    treatments given in the UK trial (with positive tested patients), or in over 7,000 self-administered
    treatments given to healthy volunteers in earlier Canadian clinical trial.
    Approval
    enovidTM was given an interim approval, by the MOH, as a medical device, in Israel and in Bahrain. It is
    also going through approval processes in other countries. Fast track approvals are available. Sales of
    enovidTM will commence in Israel in first early July 2021. enovidTM is currently being manufactured in
    Israel, by Nextar at a capacity of 10,000 bottles a day with scale up planned.

    References
    1 Akaberi D, et al. (2020). Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro.
    Redox Biology 37.
    2 Sungnak, W. et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells
    together with innate immune genes. Nat Med 26, 681-687, doi:10.1038/s41591-020- 0868-6

     

    SaNOtize Research and Development Corp.
    Suite #1-8755 Ash street
    Vancouver, BC V6P 3T3
    Akaberi1
    , a well-respected researcher, was quoted recently saying “To our knowledge, nitric oxide is the
    only substance shown so far to have a direct effect on SARS-CoV-2”
    Nitric oxide is a natural molecule produced by our body and it is widely regarded to possess antimicrobial
    properties. It has been approved, for two decades, as an inhalation treatment for newborn babies with
    pulmonary hypertension, using pressurized gas cylinders. The nitric oxide dose from enovidTM is different
    from the newborn therapy in at least two notable ways. First, enovidTM is being administered topically with
    a liquid made out of compounds approved by the FDA for use in food products, and secondly, enovidTM daily
    NO dose is 0.5% of that approved for the newborns.
    The rationale to evaluate enovidTM in nasal spray for treating COVID-19 is based on its non-systemic, topical
    NO releasing capability showing strong virucidal activity. Delivery of NO releasing liquid to the nasal cavity
    is supported in a recent study that concluded “given that nasal carriage is likely to be a key feature of
    transmission, drugs/vaccines administered intranasally could be highly effective in limiting spread of
    COVID-19 infection”.2
    enovidTM could be used daily, for prevention of infection, supported by the strong human data of
    reducing viral load in the nose. enovidTM could also potentially be used to prevent the progression of
    the disease, in the first few days of symptoms. Daily use of enovidTM will very likely prevent infections.
    Safety
    Nitric oxide gas inhaled continuously in a concentration of 20 parts per million (ppm) for 14 days has been
    approved as a drug to treat newborn babies with pulmonary hypertension, safely, for almost two decades.
    Nitric Oxide is also a natural molecule, produced in every system in our body. enovidTM, delivered as nasal
    spray, has a localized effect and produces nitric oxide at 0.5% of what is approved for treating “blue babies”.
    Further, the compounds used to create the nasal spray are food grade materials in a daily concentration
    under the Average Daily Intake guidelines. There were no adverse health events recorded in over 2000
    treatments given in the UK trial (with positive tested patients), or in over 7,000 self-administered
    treatments given to healthy volunteers in earlier Canadian clinical trial.
    Approval
    enovidTM was given an interim approval, by the MOH, as a medical device, in Israel and in Bahrain. It is
    also going through approval processes in other countries. Fast track approvals are available. Sales of
    enovidTM will commence in Israel in first early July 2021. enovidTM is currently being manufactured in
    Israel, by Nextar at a capacity of 10,000 bottles a day with scale up planned.
    https://www.youtube.com/watch?v=R2I3lnKlSxQ
    References
    1 Akaberi D, et al. (2020). Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro.
    Redox Biology 37.
    2 Sungnak, W. et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells
    together with innate immune genes. Nat Med 26, 681-687, doi:10.1038/s41591-020- 0868-6
    (2020).

     

    United Kingdom – completed phase IIb – primary efficacy endpoint achieved

    • Double blinded early treatment for people tested COVID positive, 79 subjects (39 treatment, 40 placebo)
    • Regimen: self-administration of NONS 5-6x/day
    • Results:
    • significant reduction in viral load in the treatment arm, compared to control arm, from Day 1 through 6
    • treatment arm showed 16x higher viral reduction than saline placebo arm on days 2 and 4 and 11 times on day 6
    • no adverse events from ~2000 doses

     

    Randomized, double blinded, Placebo controlled Clinical Efficacy Study Evaluating SaNOtize’s nasal spray for Early Treatment of COVID-19

    Product: NONS (nitric oxide nasal spray)

    Regimen: daily self-administration of Nasal Spray 5 times per day. Treatment arm – NONS, control – saline nasal spray. Ratio – 1:1

    Up to date : 79/110 subjects were enrolled and completed the trial. Interim analysis show      significant reduction in viral load in the treatment arm, compared to control arm, on Day 2 and Day 4.

    No adverse events have occurred.

    Study voluntarily stopped once Primary End Point was statistically achieved

     

    To date, one hundred and forty two(142) subjects have administered over 9,000 nasal spray treatments with no side effects at all

     

    UK Human Trial – Primary End Point Achieved

    üReduction in viral load reveals a mean difference of -5.22 log10 copies/ml on NONS, compared to saline control, from day 1 through to day 6 (p=0.0096).

    üAverage SARS-CoV-2 concentration was lower on NONS, as compared to placebo, by a factor of 16 at both days 2 and 4.

    üNo adverse events were recorded in the NONS group.

    üThe majority of patients in this study were positive for SARS- CoV-2 UK variants

    symptoms

    • . Forty subjects provided summary information, 15 on NONS and 25 on Placebo. Of these, 4/15 (26.7%) on NONS and 9/25 (36%) on placebo reported ‘worsening’ symptoms, BUT 3 of these 4 (with complete data) on NONS were only worse on Day 1-2, and then were ‘better’ on treatment, while those on placebo seemed to continue to get worse on treatment with the 2 placebo subjects that did improve, it wasn’t until after Day 5 on treatment. However, 1 NONS subject reported worsening symptoms (Day 11) after being off treatment, 1 placebo subject required hospitalization for COVID-19 management at Day 7, and 1 placebo subject’s symptoms remained and when re-tested was + for COVID-19, 2 days after being out of isolation. Interestingly, 7/15 (46.7%) NONS and 2/25 (8%) Placebo reported getting ‘better’ on treatment, typically by Day 2-4 on NONS treatment.

     

     

     

     

    Additional information

    Weight2 kg
    Additions

    DHL International

    X